On the heels of U.S. Food and Drug Administration approval of the over-the-counter sale of its OraQuick HIV test, OraSure Technologies Inc. of Bethlehem said it has proposed a public stock offering of up to $75 million.

Citigroup and Jefferies Capital Partners are acting as joint book-running managers.

Canaccord Genuity, Stephens Inc., ThinkEquity LLC and JMP Securities are acting as co-managers. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.